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Abstract
Among surgical intensive care unit (SICU) patients, it is difficult to distinguish bacterial sepsis 
from other causes of systemic inflammatory response syndrome (SIRS). Biomarkers have proven 
useful to identify the presence of bacterial infection. We enrolled a prospective cohort of 69 SICU 
patients with suspected sepsis and assayed the concentrations of nine biomarkers (α-2 
macroglobulin (A2M), C-reactive protein, ferritin, fibrinogen, haptoglobin, procalcitonin (PCT), 
serum amyloid A, serum amyloid P, and tissue plasminogen activator) at baseline, 24-, 48-, and 
72-hours. 42 patients (61%) had bacterial sepsis by chart review. A2M concentrations were 
significantly lower and PCT concentrations significantly higher in subjects with bacterial sepsis at 
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three of four timepoints. Using optimal cutoff values, the combination of baseline A2M and 72-
hour PCT achieved a negative predictive value of 75% (95% CI, 54%–96%). The combination of 
A2M and PCT discriminated bacterial sepsis from other SIRS among SICU patients with 
suspected sepsis.
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Introduction
It is difficult to distinguish bacterial sepsis from other causes of systemic inflammatory 
response syndrome (SIRS) in critically ill patients. The presence of two or more SIRS 
criteria with suspected infection has become the standard for sepsis diagnosis (Mouncey et 
al.; 1992; Sprung et al. 2008; COIITSS Study Investigators et al. 2010; Perner et al. 2012; 
Ranieri et al. 2012; Opal et al. 2013; ARISE Investigators et al. 2014; Holst et al. 2014). 
However the SIRS criteria have been criticized for lacking specificity for infection (Vincent 
1997; Levy et al. 2003; Sprung et al. 2006; Vincent et al. 2013; Liao et al. 2014). Given the 
morbidity and mortality associated with bacterial sepsis, as well as evidence that early 
antibiotic therapy improves mortality in severe sepsis, guidelines recommend that empiric, 
broad-spectrum antibacterial agents be administered to patients who meet the two-SIRS-
criteria standard (Kaukonen et al.; Brun-Buisson et al. 2004; Gaieski et al. 2010, 2013; 
Dellinger et al. 2013; Ferrer et al. 2014). The poor specificity of the SIRS criteria may thus 
contribute to excess use of broad, empiric antibiotics.
Surgical intensive care unit (SICU) patients, in particular, represent a population in whom 
SIRS criteria may demonstrate poor specificity for bacterial infection. The incidence of 
SIRS in the SICU exceeds the incidence in medical and cardiovascular ICUs. Prior studies 
have shown that greater than 90% of SICU patients meet SIRS criteria during their ICU stay 
(Pittet et al. 1995; Sigfrido Rangel-Frausto et al. 1995). The SICU has a higher proportion of 
culture-negative SIRS and sepsis than do medical or cardiovascular intensive care units 
(Sigfrido Rangel-Frausto et al. 1995; Andersson and Tracey 2011; Vincent et al. 2013).
Biomarkers have proven to be useful tools to distinguish the presence or absence of bacterial 
infection in specific patient populations. Procalcitonin (PCT) in particular has shown 
promise as a component of diagnostic and antibiotic stewardship strategies for respiratory 
tract infection and sepsis (Assicot et al. 1993; Schuetz et al. 1996, 2009, 2012, 2013; Christ-
Crain et al. 2004; Simon et al. 2004; Uzzan et al. 2006; Tang et al. 2007; Nobre et al. 2008). 
A combination of biomarkers may be even more useful than a single biomarker by 
increasing specificity for infection and improving the ability to discriminate true bacterial 
sepsis from other causes of SIRS (Meisner et al. 1999; Harbarth et al. 2001; Castelli et al. 
2004). To date, studies of biomarkers in sepsis have been limited in the number of biomarker 
combinations evaluated, and few studies have restricted analysis to SICU patients, a 
population in whom bacterial sepsis may be more difficult to discriminate (Hensel et al. 
1998; Meisner et al. 1998; Uzzan et al. 2006; Castelli et al. 2009; Prkno et al. 2013; Wacker 
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et al. 2013). The identification of SICU patients in whom antibacterial therapy can be safely 
stopped has the potential to aid antibiotic stewardship efforts, avoid adverse drug effects, and 
combat the evolution of drug-resistant pathogens (Fishman 2006; Dellit et al. 2007; Roberts 
et al. 2009; Luyt et al. 2014). We designed this study in companion with a study of 
biomarker performance in MICU patients with suspected sepsis (Han et al. 2015), with the 
hypothesis that optimal biomarker combinations and cutoffs may be specific to the SICU 
population.
We sought to systematically evaluate the ability of nine biomarkers, individually and in 
combination, to distinguish bacterial sepsis from other causes of SIRS in SICU patients. We 
further sought to define optimal biomarker cutoffs and sampling times to identify SICU 
patients with a low likelihood of bacterial infection.
Materials and Methods
Study Design and Setting
We prospectively enrolled patients admitted to the SICU of the Hospital of the University of 
Pennsylvania from February 2012 through May 2014. The study was approved by the 
institutional review board of the University of Pennsylvania. Because residual blood from 
routine clinical samples was used for biomarker analysis, a waiver of informed consent was 
granted.
Study Population
Patients were deemed eligible for study enrollment if they were identified as having 
presumed bacterial sepsis, defined by meeting two or more SIRS criteria and having new 
empiric antibiotic therapy initiated and blood cultures ordered within a four-hour window 
(Bone et al. 1992; Levy et al. 2003), at SICU admission or at any time during the SICU stay. 
Two or more SIRS criteria (body temperature > 38C or <36C; heart rate >90/minute; 
respiratory rate >20/minute; or white blood cell count (WBC) > 12,000 cells/uL or <4,000 
cells/uL) had to be met within four hours of the enrollment blood culture. Patients were 
ineligible if new or broadened empiric antibiotic therapy had been given for greater than four 
hours past the timepoint when baseline biomarkers were measured given the potential for 
antibiotic therapy to impact baseline procalcitonin (PCT) measures (Meisner 2014). New 
empiric antibiotic therapy was defined as the initiation of new antibiotic therapy in a patient 
previously not on any antibiotics or broadening of antibiotic therapy in a patient already 
receiving an antibiotic. Antibiotic review was performed by a physician trained in infectious 
diseases (E.L.).
SICU patients with presumed bacterial sepsis, defined as above, were excluded from 
enrollment if they had (1) a code status of “do not resuscitate,” (2) cardiopulmonary arrest 
from which they had been resuscitated, (3) documented bacterial infection treated with 
antibacterial therapy in the five days prior to enrollment, or (4) evidence of immune 
compromise (including human immunodeficiency virus (HIV) infection with CD4 cell count 
<200 cells/mm3, immunosuppressive therapy after organ transplantation, neutropenia (<500 
neutrophils/mm3), chemotherapy, receipt of >=20mg/day of prednisone for two or more 
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weeks in the preceding three months, or cystic fibrosis). These exclusions were made 
because the use of biomarkers to identify low risk for bacterial infection (and potentially 
discontinue empiric antibiotics) was believed to be less useful in patients in whom antibiotic 
management would be dictated by code status, established bacterial infection, or an a priori 
high risk of bacterial infection (i.e., immunocompromise).
Biomarker Measurements
Serum samples for biomarker measurements were obtained from residual blood samples 
from tests performed for routine clinical care and stored at −70C until testing as previously 
described (Han et al. 2015). Baseline biomarker measurements were performed at the time a 
patient met all eligibility criteria. Measurements were repeated daily for three days (24-hour, 
48-hour, and 72-hour timepoints). If multiple clinical blood samples were available, the one 
closest to the precise timepoint of interest was chosen.
Nine biomarkers were measured at each timepoint: PCT using the VIDAS BRAHMS PCT 
assay (bioMérieux, Durham, NC), a one-step immunoassay sandwich method with 
fluorescent detection, and the remaining eight (Supplementary Table 1) using the Bio-Plex 
Pro™ Human Acute Phase 5- and 4-Plex Panel Complete Kit (Bio-Rad Laboratories, 
Hercules, CA), a bead-based (xMAP technology) multiplex assay that allows for the 
simultaneous measurement of nine positive acute phase biomarkers in serum. Assays were 
performed per manufacturer’s instructions. The Bio-Plex assay was read using a Luminex 
200 reader (Luminex Corporation, Austin, TX), with samples from all four timepoints 
included in the same measurement test run, using a single lot of reagents, and each analyte 
measured in duplicate (results recorded as the mean of measurements).
Data Collection
Demographic information, comorbidities, and length of hospital and SICU stay prior to 
enrollment were recorded at baseline. Comorbidities of interest included hepatic dysfunction 
(defined as two or more of total bilirubin >2.5mg/dL, aspartate aminotransferase (AST) or 
alanine aminotransferase (ALT) greater than twice the upper limit of normal), solid or 
hematologic malignancy, diabetes mellitus, chronic kidney disease (with or without 
requiring hemodialysis), and pulmonary disease (chronic obstructive pulmonary disease or 
chronic bronchitis). APACHE II scores were calculated for patients at enrollment for all 
subjects in whom parameters were documented (Knaus et al. 1985).
Definition of Infection
The diagnosis of bacterial infection was determined retrospectively by the investigators 
using established Centers for Disease Control and Prevention (CDC) criteria (Horan et al. 
2008). Two physicians trained in infectious diseases (E.L. and J.H.H.) independently 
reviewed the subjects’ cumulative medical records, including all vital signs, provider notes, 
laboratory and radiographic results at 72 hours after enrollment. The reviewers were blinded 
to the results of biomarker testing. In cases of discordant assessments, the two reviewers 
discussed the case and made a consensus determination. The determination of bacterial 
infection by two-physician review served as the gold standard against which biomarker test 
characteristics were assessed. Two-physician review was chosen as the gold standard rather 
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than positive blood cultures given the potential for false-positive or false-negative blood 
cultures.
Statistical Analysis
We first visually explored the temporal trends in biomarker values, in aggregate and 
stratified by bacterial sepsis versus other causes of SIRS (i.e., non-bacterial sepsis or non-
infectious SIRS) using LOESS regression (with both least-squares estimator and Tukey’s 
biweight M-estimator, the latter to limit the impact of outliers). We then compared the mean 
biomarkers values between bacterial sepsis versus other SIRS groups at each timepoint using 
the Wilcoxon rank-sum test. We characterized the clinical characteristics of SICU patients 
with bacterial sepsis and other causes of SIRS using the Wilcoxon rank-sum test for 
continuous variables and the Fisher’s exact test for categorical variables. For all 
comparisons, a two-tailed p-value < 0.05 was considered significant.
Receiver-operating characteristic (ROC) curves were explored for each biomarker, and the 
discrimination of each biomarker was quantified using the area under the ROC curve (AUC, 
or C-statistic). We developed logistic regression models for pairwise combinations of each 
biomarker at each timepoint and determined each model’s discriminatory power (with and 
without an interaction term) using the AUC (Kleinbaum and Klein 2010; Austin and 
Steyerberg 2012). We then explored various cutoffs of each biomarker at various timepoints 
and pairwise combinations of biomarkers to maximize the specificity and negative predictive 
value (NPV) for bacterial sepsis relative to other SIRS. The goal of the derived algorithm 
was to maximize the NPV in order to identify patients with presumed sepsis at low 
likelihood of bacterial infection and the potential for safe discontinuation of empiric 
antibiotic therapy. Secondarily, we sought to maximize the specificity of the algorithm so 
that it would characterize a significant number of patients without bacterial infection as 
negative.
Statistical analyses were performed using Stata v13.0 (StataCorp LP, College Station, TX), 
SAS v9.3 (SAS Institute, Cary, NC), and R v3.2.1 (R Core Team 2014). Stata was used for 
data cleaning; SAS for the analysis of biomarker-combination thresholds, sensitivity, 
specificity, and predictive values; R was used for all other analyses. Figures were produced 
using R’s ggplot2 package v1.0.1 (Wickham 2010).
Results
Study Population Characteristics
A total of 199 patients were screened. Of these 130 were excluded, leaving 69 subjects for 
analysis. Reasons for exclusion included immunosuppression (52), ongoing treatment for a 
known infection (28), unavailable or incomplete laboratory samples (26), antibiotics 
broadened more than 4 hours prior to initial biomarker measurement (13), not meeting SIRS 
criteria (10), and cardiac arrest (1).
Of the 69 enrolled subjects, 42 (61%) had true bacterial sepsis based on two-physician chart 
review. (Initial independent review, prior to consensus determination, with Cohen’s kappa = 
0.76). In 14 (33%), the source was identified as bloodstream infection; in 11 (26%) as intra-
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abdominal infection; in 8 (19%) as pneumonia; in 3 (7%) as hepatobiliary infection; in 3 
(7%) as skin or soft-tissue infection; in 2 (5%) as intra-thoracic empyema; and in 2 (5%) as 
subdural empyema. Of the 42 subjects deemed to have true bacterial sepsis, 16 (38%) had 
positive blood cultures. Etiologies of SIRS in the absence of true bacterial sepsis included 
congestive heart failure, non-ST-elevation MI, pulmonary embolism, aspiration pneumonitis, 
ischemic bowel injury, perisplenic cyst rupture, and candidemia.
Table 1 compares clinical characteristics of subjects with bacterial sepsis versus other causes 
of SIRS. No significant differences were observed between the groups in age, APACHE II 
score, duration of hospital or ICU stay prior-to- or post-enrollment. Comorbidities and 
complications of subjects’ critical illness, including acute kidney injury, chronic renal 
insufficiency, hemodialysis, congestive heart failure, cirrhosis, diabetes mellitus, lung 
disease, ICU mortality, and overall mortality were also similar between groups. Only subject 
race, treated as a dichotomous variable (white or non-white), was significantly different 
between the groups: 43% of subjects with bacterial sepsis had a race categorized as non-
white versus 19% of subjects with other causes of SIRS (p = 0.04).
Biomarker measurements in SICU patients with bacterial sepsis versus other causes of 
SIRS
Figure 1 depicts the result of LOESS regression for the nine biomarkers, with fitting 
performed by least squares. (Supplemental Figure 1 depicts the same with fitting performed 
by a redescending M-estimator using Tukey’s biweight function, which minimizes the 
impact of outliers (e.g., fibrinogen)). By visual inspection, differences between groups were 
apparent in α-2 macroglobulin (A2M), ferritin (FER), and procalcitonin (PCT).
The mean times (standard deviation) from baseline biomarker measurement to the repeat 
“24-hour”, “48-hour”, and “72-hour” measurements were 23.8 (4.6) hours, 48.6 (5.9) hours, 
and 72.6 (6.1) hours, respectively. Table 2 shows the comparison of mean biomarker values 
at each of the measured timepoints between subjects with bacterial sepsis and subjects with 
other causes of SIRS, which again highlighted A2M, FER, and PCT. Significant differences 
were observed between groups for A2M at baseline (p=0.009), “24-hour” (p=0.006), and 
“48-hour” (p=0.03) timepoints; for FER at baseline (p=0.04); and for PCT at “24-hour” 
(p=0.01), “48-hour” (p=0.007), and “72-hour” (p=0.002) timepoints.
Diagnostic value of alpha-2-macroglobulin and procalcitonin
ROC curve analysis of individual biomarkers at each timepoint (Figure 2) showed that the 
discrimination between bacterial sepsis and other causes of SIRS was greatest for “72-hour” 
PCT (0.73), “48-hour” PCT (0.70), baseline A2M (0.69), “24-hour” A2M (0.69), and “24-
hour” PCT (0.69). Logistic regression models were generated for each pairwise combination 
of biomarkers, and the model AUC was calculated both with and without an interaction 
term. This analysis further highlighted the discrimination of A2M and PCT (Supplementary 
Figure 2). The greatest logistic regression model AUC was 0.76, observed with the 
combination of “24-hour” A2M and “72-hour” PCT (no interaction). The combination of 
“baseline” A2M and “72-hour” PCT was the second most discriminatory model, with an 
AUC of 0.75. The top 43 observed AUC values (ranging from 0.72–0.76) included either 
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A2M, PCT, or both. Though the combination of A2M and PCT outperformed single 
biomarkers, the difference did not achieve statistical significance: the 95% confidence 
interval of the best combined-biomarker AUC ranged from 0.64 to 0.87, overlapping the 
AUC 95% confidence interval for some single biomarker measures.
We explored a range of cutoff values for all nine biomarkers at all four timepoints, and we 
determined the measurement times and cutoff values with maximal negative predictive value 
(NPV). Table 3 lists the five combinations of A2M and PCT that achieved the greatest NPV 
in this population of SICU patients. The NPV achieved with a combination of A2M and 
PCT measurements ranged from 0.72–0.75. Specificity diminished with increasing negative 
predictive value, ranging from 0.5–0.46 for the combinations of A2M and PCT.
Discussion
In this prospective cohort study of critically ill surgical patients, we found that combinations 
of biomarkers and repeat measurements of the same biomarker were better able to 
discriminate true bacterial sepsis from other causes of SIRS than single biomarker 
measurements. A2M and PCT each demonstrated a good ability to discriminate true 
bacterial sepsis from other causes of SIRS, but their combination had greater discriminatory 
ability. The combination of “72-hour” PCT with either “baseline” A2M or “24-hour” A2M 
both demonstrated good discriminatory ability, with the “24-hour” A2M combination only 
slightly greater. We further established the measurement times and cutoff values at which 
combinations of A2M and PCT had maximal NPV. We examined both combinations in the 
NPV analysis, but favored “baseline” A2M over “24-hour” A2M given the stated aim to 
optimize an algorithm that might be applicable to cessation of empiric antibiotic therapy. By 
optimizing cutoff values of A2M and PCT, we were able to achieve an NPV of 0.75. Of 
note, the combination of A2M and PCT achieved a more favorable balance of NPV and 
specificity than did any single biomarker.
It is difficult to distinguish bacterial sepsis from other causes of SIRS in critically ill 
patients, particularly in SICU patients (Pittet et al. 1995; Sigfrido Rangel-Frausto et al. 
1995; Andersson and Tracey 2011; Vincent et al. 2013). Meeting SIRS criteria alone is not 
specific for infection. Nevertheless, in the absence of an alternative cause, infection is often 
presumed to be the cause for SIRS, and treatment guidelines direct the prescription of broad-
spectrum antibacterial therapy to patients who meet this standard because prompt treatment 
reduces the morbidity and mortality of patients with severe sepsis (Vincent 1997; Levy et al. 
2003; Sprung et al. 2006; Vincent et al. 2013; Liao et al. 2014). In this context, biomarkers 
may play a useful role. Biomarkers or combinations of biomarkers with a high NPV for 
bacterial sepsis may allow the prompt discontinuation of antibacterial therapy in patients for 
whom it is unlikely to offer any benefit (Harbarth et al. 2001; BalcI et al. 2002; Meynaar et 
al. 2011; Prkno et al. 2013; Wacker et al. 2013; Garnacho-Montero et al. 2014). Such 
antibiotic stewardship interventions are increasingly important as rates of antibiotic 
resistance rise, particularly among critically ill patients (Carlet et al. 2004; Rice 2009; for 
Healthcare Epidemiology of America 2012). But the biomarkers and biomarker 
combinations found to be most informative may depend upon the particular population of 
critically ill patients studied, given that the diseases of SICU patients (e.g., trauma, bowel 
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injury) differ significantly from those of medical or cardiovascular intensive care unit 
patients.
PCT and A2M stood out among the nine biomarkers we studied in SICU patients with 
suspected sepsis. The diagnostic utility of PCT, a peptide precursor of calcitonin produced 
by the thyroid, is well-established. A2M, a large plasma protein with anti-protease activity, 
which is produced mostly in the liver, is less well studied than PCT as a biomarker that may 
aid discrimination between bacterial sepsis and other causes of SIRS. However, it has been 
shown to decline in the setting of pancreatitis, thought in part due its binding plasmin, which 
is activated in this setting (McMahon et al. 1984; Abbink et al. 1991; Birkenmeier et al. 
2006; Pierrakos and Vincent 2010; Wacker et al. 2013; Dalli et al. 2014; Garnacho-Montero 
et al. 2014; Vandevyver et al. 2014). The breadth of biomarkers evaluated in the present 
study permitted identification of A2M as a valuable biomarker. The restriction of the present 
study to SICU patients may also have played a role. We note that in a parallel study of 
biomarkers to discriminate bacterial sepsis from other SIRS among medical intensive care 
unit (MICU) patients, CRP proved a useful adjunct to PCT -- but A2M did not discriminate 
well between bacterial sepsis and other causes of SIRS at any timepoint in the MICU. One 
hypothesis for the improved discriminatory ability of A2M among SICU patients relative to 
MICU patients relates to the documented effect of intra-abdominal inflammation upon A2M 
decline: intra-abdominal sources accounted for few cases of bacterial sepsis in the MICU 
study, but accounted for 26% of cases in this study (Han et al. 2015).
The strengths of the study we present are (1) the number of biomarkers and biomarker-
combinations evaluated, (2) the longitudinal sampling of biomarkers throughout the early 
period of suspected bacterial sepsis, and (3) the restriction to SICU patients -- a particularly 
difficult-to-diagnose population. We are unaware of any study to date that has examined 
multiple biomarkers with a focus on SICU patients.
This study’s findings must be interpreted in light of several limitations. (1) Though 
agreement between physician-reviewers was high (Cohen’s kappa = 0.76), and though each 
review was performed independently and blinded to the biomarker results, there was the 
potential for misclassification given the complexity of SICU patients and the absence of a 
gold standard for the determination of bacterial sepsis. (2) Subject race treated as a 
dichotomous variable (non-white or white) was significantly different between groups, 
which may account for some of the differences observed in A2M and PCT (though we could 
not identify literature to support race-based differences in these biomarkers). (3) It is 
plausible that the observed patterns of biomarkers may differ by source of infection, but the 
diverse sources we observed (bloodstream, intra-abdominal, pneumonia, hepatobiliary, skin 
or soft-tissue infection, intrathoracic empyema, and subdural empyema) relative to the 
number of subjects enrolled precluded stratified analysis. (4) The study was performed at a 
single, academic medical center, and it excluded immunocompromised patients -- limiting 
the populations to which our results can be generalized. Finally, (5) though the combination 
of A2M and PCT demonstrated good discriminatory ability and NPV, the NPV of 0.75 
achieved from this combination alone is not sufficient justify cessation of empiric antibiotics 
directed against bacterial sepsis. The identified biomarker combination must be integrated 
with other clinical, laboratory, and imaging data to inform antibiotic management.
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In conclusion, A2M and PCT demonstrate good discrimination between bacterial sepsis and 
other causes of SIRS among SICU patients. The combination of these two biomarkers 
performs better than either in isolation. Further study should be directed to antibiotic 
stewardship algorithms based upon this combination of biomarkers to reduce unnecessary 
antibiotic use among SICU patients with suspected bacterial sepsis.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Longitudinal Biomarker Levels Among Bacterial Sepsis and Other Causes of SIRS. LOESS 
regression relating biomarker value to actual collection time was performed for each 
biomarker in each group, with fitting performed by least squares. The line indicates the local 
mean, colored according to group (bacterial sepsis versus other causes of SIRS); the gray 
shading indicates the standard error about the mean. A2M, FER, and PCT demonstrate 
regions of separation between group means. We note that A2M differences are most 
pronounced at baseline and “24-hours” but diminish at later timepoints. The diminishing 
difference at later timepoints may reflect A2M synthesis to compensate for a rapid A2M 
decline in the early phase of sepsis. The FIB local means are highly variable due to outliers.
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Individual Biomarker Discrimination Between Bacterial Sepsis and Other Causes of SIRS.
Receiver-operating characteristic (ROC) curves are shown for each biomarker at each 
timepoint. The discrimination of each biomarker, quantified by the C-statistic (equivalent to 
the area under the ROC curve, AUC) is shown at bottom right of each panel.
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Table 1







Age (years) 64.2 (26.4) 70.1 (21.2) 0.14
APACHE II Scorec 23 (9.8) 22 (16) 0.43
Hospital Stay Prior to Enrollment (days) 7.5 (15.2) 6 (7.5) 0.64
ICU Stay Prior to Enrollment (days) 2.5 (8.8) 2 (6) 0.75
Post Enrollment Stay (days) 20.5 (18.2) 15 (18) 0.17
In-Hospital Mortality 8 (19%) 4 (15%) 0.75
ICU Mortality 7 (17%) 3 (11%) 0.73
Malignancy 10 (24%) 10 (37%) 0.28
Diabetes Mellitus 12 (29%) 6 (22%) 0.78
Congestive Heart Failure 0 (0%) 1 (4%) 0.39
Lung Disease 3 (7%) 2 (7%) >0.99
Cirrhosis 1 (2%) 1 (4%) >0.99
Chronic Renal Insufficiency 5 (12%) 7 (26%) 0.19
Acute Kidney Injury 16 (38%) 5 (19%) 0.11
Hemodialysis 2 (5%) 1 (4%) >0.99
Non-white Race 18 (43%) 5 (19%) 0.04*
a
For continuous variables, table shows median value (interquartile range); for categorical variables, table shows subject number (percentage of total 
subjects in group).
b
P-values are based on the Wilcoxon rank-sum test for continuous variables, Fisher’s exact test for categorical variables.
c
APACHE II scores could not be calculated for 18 subjects with bacterial sepsis and 6 subjects with other causes of SIRS because no blood gas 
testing was performed; missing data was excluded from analysis.
*
Significant p-values are highlighted.
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0 82.4 (38.6) 112.9 (59.6) 0.009*
24 75.3 (27.6) 96.2 (53.4) 0.006*
48 71.9 (26.4) 90.9 (60.6) 0.03*
72 76.8 (30.1) 89.1 (41) 0.05
C-reactive protein (mg/L)
0 98.5 (81.1) 90.1 (57.2) 0.66
24 121.2 (109.2) 109.9 (80.8) 0.94
48 103.2 (84.8) 110.8 (112.9) 0.41
72 94.6 (75.8) 85.1 (84.3) 0.58
Ferritin (ng/mL)
0 205.8 (305.3) 114.1 (180.6) 0.04*
24 245.8 (340) 148.6 (270) 0.18
48 242.6 (418.1) 158.6 (214.4) 0.06
72 224.1 (295.4) 127.8 (263.7) 0.05
Fibrinogen (µg/mL)
0 5.7 (2.3) 6.5 (2) 0.26
24 6.2 (3.4) 6.9 (2.9) 0.66
48 6.3 (3.2) 6.1 (1.8) 0.68
72 6 (3.4) 5.6 (2.5) 0.81
Haptoglobin (mg/dL)
0 143.4 (359.4) 102 (315.5) 0.36
24 102 (351.5) 102 (276.4) 0.36
48 143.6 (359.3) 102 (376.3) 0.81
72 115.5 (359.7) 101.9 (365.1) 0.53
Procalcitonin (ng/mL)
0 2.2 (13.8) 1 (1.8) 0.05
24 3.6 (23.2) 1.5 (2.2) 0.01*
48 2.5 (18.2) 0.8 (1.7) 0.007*
72 2.3 (12.8) 0.7 (1.6) 0.002*
Serum amyloid A (µg/mL)
0 19.8 (13.8) 24.6 (18.3) 0.12
24 25.9 (17.8) 27 (39.6) 0.25
48 23 (18.4) 27.6 (36.9) 0.17
72 23.9 (20.5) 27.7 (38.2) 0.18
Serum amyloid P (mg/L)
0 34.2 (23.1) 32.7 (15.1) 0.75
24 33.2 (20.3) 30.1 (25.5) 0.60
48 33.7 (21.3) 33.4 (21) 0.62
72 35.8 (22.5) 36.8 (19.2) 0.58
Tissue plasminogen activator (ng/mL)
0 8.3 (4.9) 6.9 (3.5) 0.32
24 7.9 (5.3) 7.4 (5.9) 0.66






















48 7.4 (6.2) 7.1 (3.7) 0.94
72 7.5 (5.8) 6.9 (3.5) 0.45
a
For each biomarker, in each group, the median value (interquartile range) is presented.
b
P-values are based upon Wilcoxon rank-sum testing.
*
Significant p-values are highlighted.
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72-hour PCT ≥0.5 & 48-hour A2M
≤150
0.72 (0.52–0.93) 13 0.5 (0.31–0.70)
72-hour PCT ≥0.5 & 72-hour A2M
≤150
0.72 (0.52–0.93) 13 0.5 (0.31–0.70)
72-hour PCT ≥0.5 & 24-hour A2M
≤150
0.74 (0.54–0.94) 14 0.54 (0.35–0.73)
72-hour PCT ≥0.5 & baseline A2M
≤200
0.75 (0.54–0.96) 12 0.46 (0.27–0.65)
72-hour PCT ≥0.5 & 72-hour A2M
≤200
0.75 (0.54–0.96) 12 0.46 (0.27–0.65)
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